Allogene Therapeutics (ALLO) Hisse Özeti
Klinik aşamada bir immüno-onkoloji şirketi olan Allogene Therapeutics, Inc. kanser ve otoimmün hastalıkların tedavisi için genetik olarak tasarlanmış allojenik T hücre tedavileri geliştirmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
ALLO Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Allogene Therapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$2.10 |
| 52 Haftanın En Yüksek Seviyesi | US$4.46 |
| 52 Haftanın En Düşük Seviyesi | US$0.98 |
| Beta | 0.46 |
| 1 Aylık Değişim | 15.38% |
| 3 Aylık Değişim | -22.79% |
| 1 Yıllık Değişim | 66.67% |
| 3 Yıllık Değişim | -59.73% |
| 5 Yıllık Değişim | -90.60% |
| Halka arzdan bu yana değişim | -91.60% |
Son Haberler & Güncellemeler
Seeking Alpha • Jul 04
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Summary Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Recent updates
Seeking Alpha • Jul 04
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Summary Allogene Therapeutics offers upside potential driven by the pivotal ALPHA3 trial for Cema-cel in first-line large B-cell lymphoma, with a key readout in mid-2027. ALLO-329’s early clinical signals in autoimmune disease, leveraging proprietary Dagger technology, set up a differentiated, scalable CAR-T platform with high-value optionality. ALLO demonstrates improving financial discipline, reducing quarterly net loss to $42.6M and extending cash runway into early 2029 following a $200.4M public offering. Valuation reflects the discounted probability of clinical success, with catalysts including a 4Q26 ALLO-329 update and mid-2027 ALPHA3 EFS readout potentially driving re-rating. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jun 26
ALLO: ALPHA3 Trial Progress Will Drive Future Reassessment Of Risk And Reward
Analysts have adjusted their average price target for Allogene Therapeutics upward by about $1, citing updated models that reflect slightly higher estimated fair value, modestly different discount rate assumptions, and revised expectations for revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent Street research around Allogene Therapeutics shows a mix of optimism and caution, with several firms adjusting ratings and price targets in response to new trial data, refreshed models, and evolving assumptions around revenue, margins, and future P/E levels.Analiz Makalesi • Apr 10
Will Allogene Therapeutics (NASDAQ:ALLO) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. By way of example, Allogene...
Yeni Anlatı • Apr 02
MRD Guided Cell Therapy And Autoimmune Focus Will Transform Long Term Opportunity
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Yeni Anlatı • Mar 19
Off The Shelf CAR T Therapies Will Reshape Lymphoma And Autoimmune Treatment Trajectories
Catalysts About Allogene Therapeutics Allogene Therapeutics develops off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?
Yeni Anlatı • Mar 05
Allogeneic CAR T Expectations Will Likely Disappoint As Trial And Cash Runway Risks Mount
Catalysts About Allogene Therapeutics Allogene Therapeutics is a biotechnology company focused on developing off the shelf allogeneic CAR T cell therapies for cancer and autoimmune diseases. What are the underlying business or industry changes driving this perspective?Analiz Makalesi • Jun 12
Shareholders May Find It Hard To Justify Increasing Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation For Now
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 18th of June Salary of US$724.0k is part of...Analiz Makalesi • Apr 02
Here's Why We're Watching Allogene Therapeutics' (NASDAQ:ALLO) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Feb 25
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model
Summary Allogene Therapeutics appears undervalued despite market skepticism, with a robust cash runway and potential breakthroughs in allogeneic CAR-T therapies. The company's lead asset, cema-cel, aims to shift CAR-T therapy to early intervention, potentially expanding its market and redefining treatment standards. ALLO-329 targets autoimmune diseases, positioning Allogene in a new market with significant unmet needs and less competition compared to oncology. Key risks include the efficacy and durability of allogeneic CAR-T therapies and manufacturing consistency, but early data and strategic positioning offer compelling upside potential. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Allogene Therapeutics: Showing Promise Despite Some Shaky Safety
Summary Allogene is among the pioneers in non-self engineered cell therapy. They have demonstrated encouraging early results in lymphoma, moving aggressively into a pivotal trial in the first-line setting. Their pivotal phase 2 trial ALPHA3 has the potential to change how large B-cell lymphoma is managed, but we won't have these results until 2026. Other projects, like their CD70-directed therapy, look promising but have concerning safety signals, and they're also a long way from approval. Read the full article on Seeking AlphaAnaliz Makalesi • Nov 22
Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 27
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies
Summary Allogene Therapeutics is a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune diseases, with a focus on Cema-cel for LBCL. ALLO's advanced gene-editing platforms, like TALEN and CRISPR/Cas9, engineer donor-derived T cells to overcome autologous therapy limitations, enhancing treatment safety and effectiveness. Cema-cel, the company’s flagship therapy, is in a pivotal Phase 2 trial (ALPHA3) for large B-cell lymphoma, with potential regulatory submission by 2027. Despite a promising pipeline, ALLO faces cash runway concerns, making it a suitable DCA “buy” for investors aware of clinical trial risks. ALLO's valuation is attractive, with a low P/B multiple and sufficient liquidity to fund operations until the ALPHA3 trial's primary data readout in 2026. Read the full article on Seeking AlphaSeeking Alpha • Jun 12
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Summary Allogene Therapeutics, Inc. initiation of phase 2 ALPHA3 study, using cema-cel for the treatment of patients with 1st-line large B-cell lymphoma, expected in mid-2024 with two data analysis in 2026. Results from phase 2 ALPHA2 trial, using cema-cel for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia, expected by end of 2024. Results from phase 1 TRAVERSE trial, using ALLO-316 for the treatment of CD70 positive clear cell renal cell carcinoma patients, expected by the end of 2024. Company gained rights from Servier to expand use of cema-cel for r/r CLL and 1st-line LBCL in European and U.K. territories; New potential to tap into >$9.5 billion market opportunity if approval is achieved for these indications. Read the full article on Seeking AlphaAnaliz Makalesi • May 30
We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
Key Insights Allogene Therapeutics to hold its Annual General Meeting on 5th of June Total pay for CEO David Chang...Seeking Alpha • Apr 01
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Summary Allogene Therapeutics has announced changes to its pipeline that extend its financial runway into 2026. The new ALPHA3 clinical trial for Allogene's Cema-Cel cancer treatment is set to begin in mid-2024, and if successful, investors could see significant returns on their investment. The company's Q42023 report evidenced its financial distress. However, the 2024 platform vision, in my opinion, will have a positive impact on its profitability in the midterm. Given the lack of short-term revenue catalysts, with clinical trials expected to yield results by the end of 2024, investors will be required to be patient, while experiencing high volatility and potential share dilutions this year. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Hissedar Getirileri
| ALLO | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 1.0% | 0.02% | 0.6% |
| 1Y | 66.7% | 36.1% | 19.5% |
Getiri vs. Endüstri: ALLO geçen yıl % 36.1 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: ALLO geçen yıl % 19.5 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| ALLO volatility | |
|---|---|
| ALLO Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: ALLO hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: ALLO 'nin haftalık oynaklığı ( 11% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2017 | 151 | Zach Roberts | allogene.com |
Klinik aşamada bir immüno-onkoloji şirketi olan Allogene Therapeutics, Inc. kanser ve otoimmün hastalıkların tedavisi için genetik olarak tasarlanmış allojenik T hücre tedavileri geliştirmekte ve ticarileştirmektedir. Protein mühendisliği, gen düzenleme, gen ekleme ve gelişmiş tescilli T hücresi üretim teknolojilerini kullanarak çoklu allojenik CAR T hücresi ürün adaylarından oluşan bir boru hattı geliştirmektedir. Şirket ayrıca büyük B hücreli lenfoma (LBCL) tedavisi için CD19'u hedefleyen mühendislik ürünü allojenik bir CAR T hücre ürün adayı olan cemacabtagene ansegedleucel'i (cema-cel) geliştirmektedir.
Allogene Therapeutics, Inc. Temel Bilgiler Özeti
| ALLO temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$731.73m |
| Kazançlar(TTM) | -US$173.76m |
| Gelir(TTM) | n/a |
0.0x
P/S Oranı-4.2x
F/K OranıALLO aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ALLO gelir tablosu (TTM) | |
|---|---|
| Gelir | US$0 |
| Gelir Maliyeti | US$131.96m |
| Brüt Kâr | -US$131.95m |
| Diğer Giderler | US$41.81m |
| Kazançlar | -US$173.76m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.50 |
| Brüt Marj | 0.00% |
| Net Kâr Marjı | 0.00% |
| Borç/Özkaynak Oranı | 0% |
ALLO uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/09 15:40 |
| Gün Sonu Hisse Fiyatı | 2026/07/09 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Allogene Therapeutics, Inc. 29 Bu analistlerden 10, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jack Allen | Baird |
| Shanshan Xu | Berenberg |
| William Pickering | Bernstein |